EFFICACY OF THE COVID VACCINE IN HEART TRANSPLANT RECIPIENTS: WHAT DO WE KNOW AND WHAT IGNORE?Infectious diseases are a well-known major complication after solid organ transplantation. Heart transplant (HT) patients have a high mortality rate after severe acute respiratory syndrome coronavirus 2 (...
This is the case for Ad26.CoV2.S, ChAdOx1 nCoV-19/AZD1222, Gam-COVID-Vac/Sputnik V andAd5-based COVID-19 vaccine. There have been no known incidences of allergy to adenovirus vaccines, unlike mRNA vaccines. Inactivated virus vaccines are a common form of vaccine that has been used ...
SARS-CoV-2 vaccine hesitancy and its relationship with health-related quality of life in patients with heart failure - pilot cross-sectional study INTRODUCTION. Heart failure (HF) is a complex disease which influences various aspects of life. The latest COVID-19 outbreak exposed that HF patients...
“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19 and rapidly emerging variants. A single-shot COVID-19 vaccine that is easy to use, distribute and administer that provides strong and long-lasting prot...
Why did the rate drop? A vaccine efficacy’s rate is calculated by comparing the number of COVID-19 infections among trial volunteers who received the vaccine versus the cases among volunteers in the placebo group. In the Brazil trial, 85 participants injected with Sinovac’s vaccinedeveloped CO...
Despite receiving the COVID-19 vaccine, SARS-CoV-2 infection poses a high risk for respiratory diseases. Abstract As of 2022, the global population has access to several mRNA and traditional inactivated vaccines. However, their effectiveness in preventing infection, hospitalization, and COVID-associat...
According to Brazil's Butantan biomedical center, the COVID-19 vaccine developed by China's Sinovac Biotech has been found to be just 50.4 percent effective in Brazilian clinical trials. The number is significantly lower than the efficacy levels previously reported. However, Sinovac ...
Evaluation of DNA vaccine in wild-type hamster model of COVID-19 disease A SARS-CoV-2 spike-based DNA vaccine, nCoV-S(JET), was constructed by cloning a human-codon-optimized gene encoding the full-length spike protein into a plasmid vector as described in Methods. The plasmid backbone use...
Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and ...
Efficacy of COVID-19 vaccine in patients with CLL Author links open overlay panelShow more Share Cite https://doi.org/10.1182/blood.2021012262Get rights and contentPrevious article in issue Next article in issue Download full text in PDF